Skip to main content

Differences Between Dihydropyridine and Non-Dihydropyridine Calcium Antagonists in Inotropic, Chronotropic, Dromotropic and Vascular Effects: Differences in Underlying Mechanism

  • Conference paper

Part of the book series: Bayer-Symposium ((BAYER-SYMP,volume 9))

Abstract

It is generally accepted that nifedipine and nicardipine, dihydropyridine (DHP) calcium antagonists (Ca-antagonists), are less cardiodepressant that verapamil and diltiazem, non-dihydropyridine (non-DHP) Ca-antagonists, in therapeutic doses used in the treatment of angina pectoris and/or hypertension. Such a property of nifedipine is indeed one of its advantages over the two non-DHP Ca-antagonists. However, owing to this property nifedipine tends to produce reflex tachycardia which is thought to be one of its undesirable effects [1]. Among new DHP Ca-antagonists developed recently PY 108–068 [2] and PN 200-110 [3] have been claimed less likely to produce reflex tachycardia. Thus, the question arises whether some of DHP Ca-antagonists produced by some modifications of the chemical structure of nifedipine possess a low separation between the vasodilator and the cardiac effects as do verapamil and diltiazem. The present article first treats this question and afterwards discusses mechanisms underlying a high separation between the vasodilator and the cardiac effects in DHP Ca-antagonists. To settle the first question the article treats seven DHP Ca-antagonists, i.e., nifedipine, nicardipine, nimodipine [4, 5], nisoldipine [6], nitrendipine [7, 8], PY 108–068 [2] and PN 200-110 [3] and three non-DHP Ca-antagonists, i.e., verapamil, diltiazem and KB-944 [9, 10].

This is a preview of subscription content, log in via an institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ebner F (1975) In: Lochner W, Braasch W, Kroneberg G (eds) 2nd International Adalat Symposium. New therapy of ischemic heart disease. Springer, Berlin Heidelberg New York, p 348.

    Google Scholar 

  2. Hof RP, Hof A, Neumann P (1982) J Cardiovasc Pharmacol 4:352.

    Article  PubMed  CAS  Google Scholar 

  3. Hof RP, Hof A, Scholtysik G, Menninger K (1984) J Cardiovasc Pharmacol 6:407.

    Article  PubMed  CAS  Google Scholar 

  4. Kazda S, Hoffmeister F (1979) Naunyn-Schmiedeberg’s Arch Pharmacol 307:R43.

    Google Scholar 

  5. Kazda S, Garthoff B, Krause HP, Schloßmann K (1982) Arzneim-Forsch 32:331.

    CAS  Google Scholar 

  6. Kazda S, Garthoff H, Meyer H, Schloßmann K, Stoepel K, Towart R, Vater W, Wehinger E (1980) Arzneim-Forsch 30:2144.

    CAS  Google Scholar 

  7. Meyer H, Bossert F, Wehinger E, Stoepel K, Vater W (1981) Arzneim-Forsch 31:407.

    CAS  Google Scholar 

  8. Knorr A, Stoepel K (1981) Arzneim-Forsch 31:2062.

    CAS  Google Scholar 

  9. Morita T, Yoshino K, Kanazawa T, Ito K, Nose T (1982) Arzneim-Forsch 32:1037.

    CAS  Google Scholar 

  10. Morita T, Kanazawa T, Ito K, Nose T (1982) Arzneim-Forsch 32:1043.

    CAS  Google Scholar 

  11. Endoh M, Hashimoto K (1970) Am J Physiol 218:1459.

    PubMed  CAS  Google Scholar 

  12. Himori N, Ono H, Taira N (1976) Jpn J Pharmacol 26:427.

    Article  PubMed  CAS  Google Scholar 

  13. Taira N, Kawada M, Satoh K (1983) J Cardiovasc Pharmacol 5:349.

    Article  PubMed  CAS  Google Scholar 

  14. Satoh K, Yanagisawa T, Taira N (1981) Clin Exp Pharmacol Physiol 7:249.

    Article  Google Scholar 

  15. Satoh K, Kawada M, Wada Y, Taira N (1984) Arzneim-Forsch 34:563.

    CAS  Google Scholar 

  16. Takahashi K, Taira N (to be published) Arzneim-Forsch.

    Google Scholar 

  17. Satoh K, Wada Y, Taira N (1986) Arzneim-Forsch.

    Google Scholar 

  18. Wada Y, Satoh K, Taira N (1984) J Cardiovasc Pharmacol 6:881.

    Article  PubMed  CAS  Google Scholar 

  19. Wada Y, Satoh K, Taira N (1985) J Cardiovasc Pharmacol 7:190.

    Article  PubMed  CAS  Google Scholar 

  20. Endoh M, Kimura T, Hashimoto H (1974) Jpn J Pharmacol 24:771.

    Article  CAS  Google Scholar 

  21. Kubota K, Hashimoto K (1973) Naunyn-Schmiedeberg’s Arch Pharmacol 278:135.

    Article  CAS  Google Scholar 

  22. Hashimoto K, Iijima T, Hashimoto K, Taira N (1972) Tohoku J Exp Med 107:263.

    Article  PubMed  CAS  Google Scholar 

  23. Ono H, Himori N, Taira N (1977) Tohoku J Exp Med 121:383.

    Article  PubMed  CAS  Google Scholar 

  24. Narimatsu A, Taira N (1976) Naunyn-Schmiedeberg’s Arch Pharmacol 294:169.

    Article  CAS  Google Scholar 

  25. Endoh M, Yanagisawa T, Taira N (1978) Naunyn-Schmiedeberg’s Arch Pharmacol 302:235.

    Article  CAS  Google Scholar 

  26. Taira N (1979) In: Bing RJ (ed) New drug therapy with a calcium antagonist. Diltiazem Hakone Symposium 1978. Excerpta Medica, Amsterdam Princeton, p 91.

    Google Scholar 

  27. Iijima T, Yanagisawa T, Taira N (1984) J Moll Cell Cardiol 16:1173.

    Article  CAS  Google Scholar 

  28. Sakamoto N, Terai M, Takenaka T, Maeno H (1978) Biochem Pharmacol 27:1269.

    Article  PubMed  CAS  Google Scholar 

  29. Nishikori K, Takenaka T, Maeno H (1981) Jpn J Pharmacol 31:701.

    Article  PubMed  CAS  Google Scholar 

  30. Norman JA, Ansell J, Phillips MA (1983) Eur J Pharmacol 93:107.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 1985 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Taira, N. (1985). Differences Between Dihydropyridine and Non-Dihydropyridine Calcium Antagonists in Inotropic, Chronotropic, Dromotropic and Vascular Effects: Differences in Underlying Mechanism. In: Fleckenstein, A., Van Breemen, C., Gross, R., Hoffmeister, F. (eds) Cardiovascular Effects of Dihydropyridine-Type Calcium Antagonists and Agonists. Bayer-Symposium, vol 9. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-70499-4_24

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-70499-4_24

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-70501-4

  • Online ISBN: 978-3-642-70499-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics